Administration and dosage of diaminophenothiazines
AssigneeWisTa Laboratories Ltd.
InventorsClaude Michel Wischik, Bjorn Olaf Schelter, Damon Jude Wischik, John Mervyn David Storey
Life of this patent
Estimating the term…
Abstract
The invention provides novel regimens for treatment of neurodegenerative disorders utilising methylthioninium (MT)-containing compounds. The regimens are based on novel findings in relation to the dosage of MT compounds, and their interaction with symptomatic treatments based on modulation of acetylcholinesterase levels.
Claims22
A method of therapeutic treatment of mild cognitive impairment in a subject,
- which method comprises orally administering once per day to said subject a methylthioninium (MT)-containing compound,
- wherein said administration provides a total daily dose of between 0.5 and 20 mg of MT to the subject per day,
- wherein the MT compound is a compound of the following formula (“LMTX”):
- wherein each of HnA and HnB (where present) are protic acids which may be the same or different,
- and wherein p=1 or 2;
- q=0 or 1;
- n=1 or 2;
- (p+q)×n=2.
(canceled)
4-11. (canceled)
13-14. (canceled)
17-18. (canceled)
25-37. (canceled)
The method of prophylactic treatment of mild cognitive impairment in a subject,
- which method comprises orally administering once per day to said patient a methylthioninium (MT)-containing compound,
- wherein said administration provides a total daily dose of between 0.5 and 20 mg of MT to the subject per day,
- wherein the MT compound is a compound of the following formula (“LMTX”):
- wherein each of HnA and HnB (where present) are protic acids which may be the same or different,
- and wherein p=1 or 2;
- q=0 or 1;
- n=1 or 2;
- (p+q)×n=2.
39-40. (canceled)
44-84. (canceled)
Dependencies are inferred from the claim text.